Cargando…

Combined Modality Therapy Based on Hybrid Gold Nanostars Coated with Temperature Sensitive Liposomes to Overcome Paclitaxel-Resistance in Hepatic Carcinoma

In this study, we prepared gold nanostar (GNS) composite nanoparticles containing siRNA of cyclooxygenase-2(siCOX-2) that were modified by tumor targeting ligand 2-deoxyglucose (DG) and transmembrane peptide 9-poly-D-arginine (9R) to form siCOX-2(9R/DG-GNS). Paclitaxel loaded temperature sensitive l...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Hongyan, Han, Weili, Gan, Ye, Li, Qiaofeng, Li, Xiaolan, Shao, Lanlan, Zhu, Dan, Guo, Hongwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6969923/
https://www.ncbi.nlm.nih.gov/pubmed/31847496
http://dx.doi.org/10.3390/pharmaceutics11120683
_version_ 1783489411685548032
author Zhu, Hongyan
Han, Weili
Gan, Ye
Li, Qiaofeng
Li, Xiaolan
Shao, Lanlan
Zhu, Dan
Guo, Hongwei
author_facet Zhu, Hongyan
Han, Weili
Gan, Ye
Li, Qiaofeng
Li, Xiaolan
Shao, Lanlan
Zhu, Dan
Guo, Hongwei
author_sort Zhu, Hongyan
collection PubMed
description In this study, we prepared gold nanostar (GNS) composite nanoparticles containing siRNA of cyclooxygenase-2(siCOX-2) that were modified by tumor targeting ligand 2-deoxyglucose (DG) and transmembrane peptide 9-poly-D-arginine (9R) to form siCOX-2(9R/DG-GNS). Paclitaxel loaded temperature sensitive liposomes (PTX-TSL) were surface-modified to produce PTX-TSL-siCOX-2(9R/DG-GNS) displaying homogeneous star-shaped structures of suitable size (293.93 nm ± 3.21) and zeta potentials (2.47 mV ± 0.22). PTX-TSL-siCOX-2(9R/DG-GNS) had a high thermal conversion efficiency under 808 nm laser radiation and a superior transfection efficiency, which may be related to the targeting effects of DG and increased heat induced membrane permeability. COX-2 expression in HepG2/PTX cells was significantly suppressed by PTX-TSL-siCOX-2(9R/DG-GNS) in high temperatures. The co-delivery system inhibited drug-resistant cell growth rates by ≥77% and increased the cell apoptosis rate about 47% at elevated temperatures. PTX-TSL and siCOX-2 loaded gold nanostar particles, therefore, show promise for overcoming tumor resistance.
format Online
Article
Text
id pubmed-6969923
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69699232020-02-04 Combined Modality Therapy Based on Hybrid Gold Nanostars Coated with Temperature Sensitive Liposomes to Overcome Paclitaxel-Resistance in Hepatic Carcinoma Zhu, Hongyan Han, Weili Gan, Ye Li, Qiaofeng Li, Xiaolan Shao, Lanlan Zhu, Dan Guo, Hongwei Pharmaceutics Article In this study, we prepared gold nanostar (GNS) composite nanoparticles containing siRNA of cyclooxygenase-2(siCOX-2) that were modified by tumor targeting ligand 2-deoxyglucose (DG) and transmembrane peptide 9-poly-D-arginine (9R) to form siCOX-2(9R/DG-GNS). Paclitaxel loaded temperature sensitive liposomes (PTX-TSL) were surface-modified to produce PTX-TSL-siCOX-2(9R/DG-GNS) displaying homogeneous star-shaped structures of suitable size (293.93 nm ± 3.21) and zeta potentials (2.47 mV ± 0.22). PTX-TSL-siCOX-2(9R/DG-GNS) had a high thermal conversion efficiency under 808 nm laser radiation and a superior transfection efficiency, which may be related to the targeting effects of DG and increased heat induced membrane permeability. COX-2 expression in HepG2/PTX cells was significantly suppressed by PTX-TSL-siCOX-2(9R/DG-GNS) in high temperatures. The co-delivery system inhibited drug-resistant cell growth rates by ≥77% and increased the cell apoptosis rate about 47% at elevated temperatures. PTX-TSL and siCOX-2 loaded gold nanostar particles, therefore, show promise for overcoming tumor resistance. MDPI 2019-12-15 /pmc/articles/PMC6969923/ /pubmed/31847496 http://dx.doi.org/10.3390/pharmaceutics11120683 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zhu, Hongyan
Han, Weili
Gan, Ye
Li, Qiaofeng
Li, Xiaolan
Shao, Lanlan
Zhu, Dan
Guo, Hongwei
Combined Modality Therapy Based on Hybrid Gold Nanostars Coated with Temperature Sensitive Liposomes to Overcome Paclitaxel-Resistance in Hepatic Carcinoma
title Combined Modality Therapy Based on Hybrid Gold Nanostars Coated with Temperature Sensitive Liposomes to Overcome Paclitaxel-Resistance in Hepatic Carcinoma
title_full Combined Modality Therapy Based on Hybrid Gold Nanostars Coated with Temperature Sensitive Liposomes to Overcome Paclitaxel-Resistance in Hepatic Carcinoma
title_fullStr Combined Modality Therapy Based on Hybrid Gold Nanostars Coated with Temperature Sensitive Liposomes to Overcome Paclitaxel-Resistance in Hepatic Carcinoma
title_full_unstemmed Combined Modality Therapy Based on Hybrid Gold Nanostars Coated with Temperature Sensitive Liposomes to Overcome Paclitaxel-Resistance in Hepatic Carcinoma
title_short Combined Modality Therapy Based on Hybrid Gold Nanostars Coated with Temperature Sensitive Liposomes to Overcome Paclitaxel-Resistance in Hepatic Carcinoma
title_sort combined modality therapy based on hybrid gold nanostars coated with temperature sensitive liposomes to overcome paclitaxel-resistance in hepatic carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6969923/
https://www.ncbi.nlm.nih.gov/pubmed/31847496
http://dx.doi.org/10.3390/pharmaceutics11120683
work_keys_str_mv AT zhuhongyan combinedmodalitytherapybasedonhybridgoldnanostarscoatedwithtemperaturesensitiveliposomestoovercomepaclitaxelresistanceinhepaticcarcinoma
AT hanweili combinedmodalitytherapybasedonhybridgoldnanostarscoatedwithtemperaturesensitiveliposomestoovercomepaclitaxelresistanceinhepaticcarcinoma
AT ganye combinedmodalitytherapybasedonhybridgoldnanostarscoatedwithtemperaturesensitiveliposomestoovercomepaclitaxelresistanceinhepaticcarcinoma
AT liqiaofeng combinedmodalitytherapybasedonhybridgoldnanostarscoatedwithtemperaturesensitiveliposomestoovercomepaclitaxelresistanceinhepaticcarcinoma
AT lixiaolan combinedmodalitytherapybasedonhybridgoldnanostarscoatedwithtemperaturesensitiveliposomestoovercomepaclitaxelresistanceinhepaticcarcinoma
AT shaolanlan combinedmodalitytherapybasedonhybridgoldnanostarscoatedwithtemperaturesensitiveliposomestoovercomepaclitaxelresistanceinhepaticcarcinoma
AT zhudan combinedmodalitytherapybasedonhybridgoldnanostarscoatedwithtemperaturesensitiveliposomestoovercomepaclitaxelresistanceinhepaticcarcinoma
AT guohongwei combinedmodalitytherapybasedonhybridgoldnanostarscoatedwithtemperaturesensitiveliposomestoovercomepaclitaxelresistanceinhepaticcarcinoma